BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25069038)

  • 1. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
    Wu J; Waxman DJ
    Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
    Wu J; Jordan M; Waxman DJ
    BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
    Chen CS; Doloff JC; Waxman DJ
    Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
    Jordan M; Waxman DJ
    Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.
    Du B; Waxman DJ
    Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.
    Doloff JC; Waxman DJ
    BMC Cancer; 2015 May; 15():375. PubMed ID: 25952672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
    Doloff JC; Waxman DJ
    Cancer Res; 2012 Mar; 72(5):1103-15. PubMed ID: 22237627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
    Doloff JC; Chen CS; Waxman DJ
    Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
    Wu J; Waxman DJ
    Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
    Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
    NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance.
    Tran AP; Ali Al-Radhawi M; Kareva I; Wu J; Waxman DJ; Sontag ED
    Front Immunol; 2020; 11():1376. PubMed ID: 32695118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.
    Jia L; Waxman DJ
    Cancer Lett; 2013 Apr; 330(2):241-9. PubMed ID: 23228633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
    Banissi C; Ghiringhelli F; Chen L; Carpentier AF
    Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine breast cancer.
    Vergato C; Doshi KA; Roblyer D; Waxman DJ
    Cancer Res Commun; 2022 Apr; 2(4):246-257. PubMed ID: 36187936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E; Barichello JM; Ishida T; Kiwada H
    Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
    Jounaidi Y; Waxman DJ
    Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice.
    Emmenegger U; Shaked Y; Man S; Bocci G; Spasojevic I; Francia G; Kouri A; Coke R; Cruz-Munoz W; Ludeman SM; Colvin OM; Kerbel RS
    Mol Cancer Ther; 2007 Aug; 6(8):2280-9. PubMed ID: 17671082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.
    Doloff JC; Khan N; Ma J; Demidenko E; Swartz HM; Jounaidi Y
    Curr Cancer Drug Targets; 2009 Sep; 9(6):777-88. PubMed ID: 19754361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas.
    Mupparaju S; Hou H; Lariviere JP; Swartz H; Jounaidi Y; Khan N
    Oncol Rep; 2011 Jul; 26(1):281-6. PubMed ID: 21503586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.
    Fulci G; Breymann L; Gianni D; Kurozomi K; Rhee SS; Yu J; Kaur B; Louis DN; Weissleder R; Caligiuri MA; Chiocca EA
    Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12873-8. PubMed ID: 16908838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.